Brief: Belite Bio Doses First Subject In Late-Stage Trial For Eye Disease
27/07/2023 22:20
July 27 (Reuters) - Belite Bio Inc BLTE.O :
* BELITE BIO DOSES FIRST SUBJECT IN PIVOTAL PHASE 3 PHOENIX
TRIAL
EVALUATING ORAL TINLAREBANT FOR GA
* BELITE BIO INC: ENROLLMENT OF APPROXIMATELY 430 GA
SUBJECTS
ACROSS MULTIPLE CENTERS GLOBALLY
* BELITE BIO INC - INTERIM ANALYSIS OF EFFICACY AND SAFETY
IS
EXPECTED TO BE CONDUCTED AT MID-POINT OF TRIAL
Source text for Eikon: ID:nGNX3VmBvV
Further company coverage: BLTE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Belite Bio
See all newsBrief: Belite Bio Announces Uplisting To The Nasdaq Global Select Market
Brief: Belite Bio Announces Multi-Market Submission Of Marketing Authorization Applications Via The Access Consortium Pathway For Tinlarebant For The Treatment Of Stargardt Disease Type 1
Brief: Belite Bio Announces Submission Of New Drug Application To The Ministry Of Health, Labour, And Welfare In Japan Under The Sakigake Designation System For Tinlarebant For The Treatment Of Stargardt Disease Type 1
Belite Bio, Inc reports results for the quarter ended June 30 - Earnings Summary
Belite Bio Q2 net loss widens on higher expenses